Growing ranks of researchers on the spectrum are overcoming barriers—from neurotypical bias to sensory sensitivities—to shape autism science.

Labs are trying to figure out who will care for animals and organoids and some clinical trials are put on hold.

Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.

Experimental surgeries to prevent seizures may help scientists understand the link between autism and epilepsy.

Independent scientists say the original analysis is flawed; the authors stand by their work and are seeking outside statisticians to reanalyze the data.

Signaling imbalance, driven by too much excitatory activity, may be a consequence of whatever brain changes lead to autism rather than a cause of the condition.

Scientists are finding patterns in symptoms among a handful of people with mutations in HNRNPU.